What the study found
ADHD medicines showed different dose-effect patterns depending on the drug class and age group. Some drugs reached a point where higher doses did not appear to add benefit, while higher doses of some medicines were linked to more discontinuation because of adverse events.
Why the authors say this matters
The authors conclude that these findings challenge both accepting suboptimal response without further dose adjustment and increasing doses beyond licensed limits when harms may outweigh expected benefits. They say the findings can inform clinical guidelines and support shared decision making about ADHD medication dosage.
What the researchers tested
The researchers did a systematic review and dose-effect network meta-analysis of double-blind randomised controlled trials of oral monotherapy for ADHD in people aged 5 years and older who met standardised ADHD criteria. They assessed efficacy using validated clinical scales and tolerability using discontinuation due to adverse events, and analyzed children/adolescents separately from adults.
What worked and what didn't
In children and adolescents, methylphenidate, amphetamines, and guanfacine showed increasing median efficacy up to 45 mg/day, 25 mg/day, and 4 mg/day, respectively, with no evidence of extra benefit above those doses, although higher-dose estimates had wide credible intervals. In adults, amphetamines appeared to plateau above about 50 mg/day, while methylphenidate efficacy increased without evidence of a plateau, possibly because data were sparse. Dose-dependent increases in discontinuation due to adverse events were seen for amphetamines above 25 mg/day in children and 50 mg/day in adults, and for methylphenidate above 50 mg/day in adults; atomoxetine and modafinil showed no dose-effect patterns in the analyses reported.
What to keep in mind
The study excluded people with genetic syndromes, treatment-resistant populations, and withdrawal-phase designs. Ethnicity or race was inconsistently reported across trials, and the authors note that some higher-dose estimates had wide credible intervals and that sparse data may have affected adult methylphenidate results.
Key points
- The study found distinct dose-effect patterns by ADHD medication class and age group.
- In children and adolescents, methylphenidate, amphetamines, and guanfacine increased in efficacy up to specific doses, with no clear added benefit above them.
- Dose-related increases in discontinuation due to adverse events were seen for amphetamines and adult methylphenidate at higher doses.
- Atomoxetine and modafinil showed no dose-effect patterns in the reported analyses.
- The authors say the findings may inform clinical guidelines and shared decision making about dosage.
Disclosure
- Research title:
- ADHD medication benefits and harms vary by dose, age, and drug
Get the weekly research newsletter
Stay current with peer-reviewed research without reading academic papers — one filtered digest, every Friday.